The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

Cathie Wood, chief of Ark Investment Management, frequently adjusts her top positions, adding to a holding when the stock falls and selling when it rises. Last week, she made some eye-catching buys as ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel ...

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance ...

The global healthtech market is experiencing rapid growth due to increasing health awareness and preventive care and the surge in the ageing popul ...

BofA lowered the firm’s price target on Tempus AI (TEM) to $48 from $60 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Nancy Pelosi’s only profitable 2025 stock, Tempus AI is in radar after insider trading filings revealed over $1.34 million in ...

Detailed price information for Coreweave Inc Cl A (CRWV-Q) from The Globe and Mail including charting and trades.

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.